<DOC>
	<DOCNO>NCT00044486</DOCNO>
	<brief_summary>This trial high risk patient determine safety efficacy posaconazole vs. fluconazole prophylaxis development invasive fungal infection . Profound , prolong neutropenia ( Absolute neutrophil count &lt; 500 cells/cubic mm least 7 day ) due induction chemotherapy acute myelogenous leukemia , myelodysplastic syndrome . Treatment Duration : maximum 12 week Follow-Up 2 month . Endpoints : incidence proven probable IFI accord EORTC/MSG criterion within neutropenic episode within 100 day randomization determine external expert review .</brief_summary>
	<brief_title>Prophylaxis Trial Posaconazole Versus Standard Azole Therapy Neutropenic Patients ( Study P01899 )</brief_title>
	<detailed_description>This study design determine safety , tolerance efficacy POZ use prophylaxis IFI high-risk subject prolong profound neutropenia . The primary objective ass efficacy SCH 56592 v fluconazole itraconazole prevent proven probable IFI neutropenic episode .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Adults adolescent ( age &gt; 13 year ) weight &gt; 34kg , either gender Disease definition : Anticipated document prolonged neutropenia ( ANC &lt; 500/mm3 2 ) Eastern Cooperative Oncology Group ( ECOG ) performance score less 3 . Female subject childbearing age must use medically accept method birth control begin studydrug treatment agree continue use study surgically sterilize ( eg , hysterectomy tubal ligation ) . Female subject childbearing potential must negative serum pregnancy test ( betahcG ) Baseline within 72 hour start study drug . Female subject pregnant , intend become pregnant , nursing . Excluded prior treatment : Subjects previously treat AMB , FLZ , ITZ proven probable IFI within 30 day enrollment . Excluded treatment prior specific study phase : Subjects take follow drug : know interact azoles may lead lifethreatening side effect . Subjects use investigational drug biologic agent chemotherapy regimen within 30 day study entry . Subjects participate blind clinical study within 30 day study entry . Subjects renal insufficiency ( estimate creatinine clearance le 20 mL/minute Baseline likely require dialysis study ) . Subjects ECG prolong QTc interval manual reading : QTc great 450 msec men great 470 msec woman . Subjects moderate severe liver dysfunction baseline , define aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase level great 5 time upper limit normal ( ULN ) , total bilirubin level great 3 time ULN .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prophylaxis</keyword>
	<keyword>neutropenia</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>fungal infection</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Anticipated prolonged profound neutropenia</keyword>
</DOC>